



TML: CS: 2022-23

08th November, 2022

Listing Department,
BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400001

Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

Sub: Media Release - Financial Results for the Half year ended 30th September, 2022.

Ref: 1. BSE Scrip Code: 530199

2. NSE Scrip Code: THEMISMED

Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Media Release issued by the Company on its financial results for the half year/Six months ended 30th September, 2022.

This is for your information and records.

Thanking you,

Yours Faithfully,
For **Themis Medicare Limited**,

Sangameshwar Iyer
Company Secretary & Compliance Officer

Encl: a/a

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com

Financial Highlights

H1 FY23 Revenue at Rs. 185.44 crore

H1 FY23 EBITDA at Rs. 41.70 crore

H1 FY23 EBITDA Margin at 22.49%

H1 FY23 PAT at Rs. 35.18 crore

H1 FY23 PAT Margin at 18.97%

Key Financials (Rs. Crore): -

Particulars	Q2 FY23	Q2 FY22	Y-o-Y	Q1 FY23	H1 FY23	H1 FY22	Y-o-Y
Revenue from Operations	91.00	107.39		94.44	185.44	219.89	
EBITDA	21.34	23.46		20.36	41.70	63.93	
EBITDA%	23.45%	21.85%	160 bps	21.56%	22.49%	29.07%	(658 bps)
PAT	17.78	19.28		17.40	35.18	50.47	
PAT%	19.54%	17.95%	159 bps	18.43%	18.97%	22.95%	(398 bps)

Performance Highlights:-

For the quarter ended September 30th, 2022:

- Revenue from Operations stood at Rs. 91.00 crore in Q2 FY23, as against Rs. 107.39 crore in Q2 FY22, decrease of 15.26%
- EBITDA for the quarter was Rs. 21.34 crore as against Rs. 23.46 crore in Q2 FY22, decrease of 9.02% - EBITDA Margin stood at 23.45%
- Q2 FY23 Profit stood at Rs. 17.78 crore as against profit of Rs. 19.28 crore in Q2 FY22, decrease of 7.76% - PAT Margin stood at 19.54%
- EPS for the quarter stood at Rs. 19.33

For the half year ended September 30th, 2022:

- Revenue from Operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, decrease of 15.67%
- EBITDA for the six months was Rs. 41.70 crore as against Rs. 63.93 crore in H1 FY22, decrease of 34.77% - EBITDA Margin stood at 22.49%

Themis Medicare Limited



- H1 FY23 Profit stood at Rs. 35.18 crore as against profit of Rs. 50.47 crore in H1 FY22, decrease of 30.29% - PAT Margin stood at 18.97%
- EPS for the period stood at Rs. 38.24

For more details, please visit: www.themismedicare.com

For any Investor Relations query, please contact:

Mr. Sangameshwar Iyer Themis Medicare Limited Email: sangameshwar.iyer@themismedicare.com	Mr. Amit Sharma / Ms. Disha Shah Adfactors PR Pvt. Ltd Email: amit.sharma@adfactorspr.com / disha.shah@adfactorspr.com
--	--

Caution Concerning Forward- Looking Statements:

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.